Insulet Corporation which can be found using ticker (PODD) have now 17 market analysts covering the stock. The analyst consensus now points to a rating of ‘buy’. The range between the high target price and low target price is between 365 and 219 with the average target price sitting at $305.00. Given that the stocks previous close was at $205.11 and the analysts are correct then there would likely be a percentage uptick in value of 48.7%. It’s also worth noting that there is a 50 day moving average of $269.96 and the 200 day moving average is $292.78. The total market capitalization for the company now stands at 13.72B. The stock price is currently at: 196.52 USD
The potential market cap would be $20,404,082,361 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 228.51, revenue per share of 21.06 and a 2.06% return on assets.
Insulet Corporation is primarily engaged in the development, manufacture and sale of its Omnipod System, a continuous insulin delivery system for people with insulin-dependent diabetes. The Omnipod System includes the Omnipod Insulin Management System (Classic Omnipod), the Omnipod DASH Insulin Management System (Omnipod DASH), and the Omnipod 5 Automated Insulin Delivery System (Omnipod 5). The Omnipod System features a small, lightweight, self-adhesive disposable tubeless Omnipod device (Pod) that the user fills with insulin and wears directly on the body for up to three days at a time, which delivers personalized doses of insulin, and the Personal Diabetes Manager (PDM) or Controller, a wireless, handheld device that programs the Pod with the user’s personalized insulin-delivery instructions and wirelessly monitors the Pod’s operation. The Company sells Pods to Amgen Inc. (Amgen) for use in the Neulasta Onpro kit, a delivery system for Amgen’s Neulasta.
